Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP565081.RALDhSnDY_ZeA_yhv4vW-_vD9tOOzAQIKn1aGqH4FjuDw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP565081.RALDhSnDY_ZeA_yhv4vW-_vD9tOOzAQIKn1aGqH4FjuDw130_assertion type Assertion NP565081.RALDhSnDY_ZeA_yhv4vW-_vD9tOOzAQIKn1aGqH4FjuDw130_head.
- NP565081.RALDhSnDY_ZeA_yhv4vW-_vD9tOOzAQIKn1aGqH4FjuDw130_assertion description "[Collectively, the data suggest that the human mAb 1F5, which has recently entered clinical development under the name CDX-1127, may provide direct antitumor activity against CD27-expressing lymphoma or leukemia, independent of its potential to enhance immunity through its agonistic properties.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP565081.RALDhSnDY_ZeA_yhv4vW-_vD9tOOzAQIKn1aGqH4FjuDw130_provenance.
- NP565081.RALDhSnDY_ZeA_yhv4vW-_vD9tOOzAQIKn1aGqH4FjuDw130_assertion evidence source_evidence_literature NP565081.RALDhSnDY_ZeA_yhv4vW-_vD9tOOzAQIKn1aGqH4FjuDw130_provenance.
- NP565081.RALDhSnDY_ZeA_yhv4vW-_vD9tOOzAQIKn1aGqH4FjuDw130_assertion SIO_000772 22589397 NP565081.RALDhSnDY_ZeA_yhv4vW-_vD9tOOzAQIKn1aGqH4FjuDw130_provenance.
- NP565081.RALDhSnDY_ZeA_yhv4vW-_vD9tOOzAQIKn1aGqH4FjuDw130_assertion wasDerivedFrom befree-20140225 NP565081.RALDhSnDY_ZeA_yhv4vW-_vD9tOOzAQIKn1aGqH4FjuDw130_provenance.
- NP565081.RALDhSnDY_ZeA_yhv4vW-_vD9tOOzAQIKn1aGqH4FjuDw130_assertion wasGeneratedBy ECO_0000203 NP565081.RALDhSnDY_ZeA_yhv4vW-_vD9tOOzAQIKn1aGqH4FjuDw130_provenance.